Effects and safety of Tizanidine in reducing knee pain after total knee arthroplasty. A randomized, double-blind, controlled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400091102

Enrollment

Unknown

Registered

2024-10-21

Start date

2024-10-26

Completion date

Unknown

Last updated

2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

Control group:Oral placebo, 2mg tid, was taken on the first day after surgery for 14 days

Tizanidine hydrochloride group:Oral tizanidine hydrochloride tablets, 2mg tid, were taken on the first day after surgery for 14 days

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients between the ages of 18 and 80 years who received TKA for primary unilateral knee osteoarthritis.

Exclusion criteria

Exclusion criteria: (1)BMI>40 kg/m2; (2) Allergic to tizanidine hydrochloride; (3) Patients with myasthenia gravis or muscle strength grade II or lower, history of cerebrovascular accident, peptic ulcer, recent myocardial infarction, mental disorders, severe metabolic, endocrine, or electrolyte disorders, and severe renal or liver dysfunction.

Design outcomes

Primary

Measure	Time frame
Postoperative pain score;	—

Secondary

Measure	Time frame
Postoperative knee function;Morphine consumption;complication;Serum inflammatory biomarkers;Range of knee motion;	—

Countries

China

Contacts

Public ContactZongke Zhou

West China Hospital, Sichuan University

zhouzongke@scu.edu.cn+86 189 8060 1028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026